Science & health
UK regulator recalls clopidogrel oral liquids after batches found under-strength
Xeal Pharma is recalling all previously produced batches of its clopidogrel oral suspension and solution after finding they contained about 76% of the labelled dose. The UK regulator says patients may not receive their prescribed amount, although no harm has been reported and long-term preventative-treatment risk is judged limited. Patients should not stop clopidogrel abruptly; pharmacists and prescribers are expected to review affected treatments and arrange alternatives where necessary.
Editorial summary · Publisher article
What matters
- The recall applies at patient, pharmacy and wholesaler level to all affected batches.
- Pharmacists are asked to identify patients supplied since 20 July 2026 if batch records are unavailable.
- Future stock is expected to be manufactured using corrected strength calculations.
Context & caveats
- Patients with affected medicine should seek advice from a pharmacist, prescriber or other healthcare professional before changing treatment.
Why this made the edition
An official medicine recall provides specific product, dosage, batch and patient-safety information with clear consequences for healthcare professionals and patients.
Source material